Ad26.COV2.S COVID-19 Vaccine Safety And Immunogenicity in Adolescents 16-17 Years of Age

J Pediatric Infect Dis Soc. 2024 Nov 27;13(11):599-601. doi: 10.1093/jpids/piae098.

Abstract

2.5 × 1010 vp Ad26.COV2.S elicited robust SARS-CoV-2-specific antibody responses in adolescents through 6 months, with acceptable safety and reactogenicity profiles. Compared with adults immunized with 5 × 1010 vp Ad26.COV2.S, adolescents had higher antibody levels, despite being vaccinated with a lower dose.

Keywords: Ad26.COV2.S; COVID-19; adolescents; infectious diseases; vaccine/immunization.

MeSH terms

  • Ad26COVS1* / adverse effects
  • Ad26COVS1* / immunology
  • Adolescent
  • Adult
  • Antibodies, Viral* / blood
  • COVID-19* / immunology
  • COVID-19* / prevention & control
  • Female
  • Humans
  • Immunogenicity, Vaccine*
  • Male

Substances

  • Ad26COVS1
  • Antibodies, Viral